Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 1 · 20%High 0 · 0%

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Overall survival · women with recurrent or FIGO stage IVB cervical cancer

Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
HR 0.9 [0.51, 1.6]
1 study · 52 participants
Low

Hysterectomy (simple or radical) with chemoradiotherapy vs internal radiotherapy (brachytherapy) with chemoradiotherapy

Death (all causes) · women with locally advanced cervical cancer

Hysterectomy (simple or radical) with chemoradiotherapy showed no clear difference in overall survival Median compared with internal radiotherapy (brachytherapy) with chemoradiotherapy (low certainty).

1 finding from 1 review

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
HR 0.65 [0.35, 1.21]
1 study · 211 participants
Low

Intervention not reported

5‐year overall survival rate (3 to 6 yr) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 5‐year overall survival rate (3 to 6 yr) (low certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 0.93 [0.84, 1.04]
2 studies · 912 participants
Low

Intervention not reported

10‐year overall survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 10‐year overall survival rate (5 to 15 yr) (moderate certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 0.79 [0.52, 1.2]
1 study · 430 participants
Moderate

Intervention not reported

3‐year overall survival rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 3‐year overall survival rate (37.2/40.2 mo) (low certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 0.95 [0.79, 1.15]
1 study · 206 participants
Low